PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | C0876973|pulmonary infections |
| Sentences | 7 |
| PubMedID- 23152277 | Background: the antibiotics used to treat pulmonary infections in people with cystic fibrosis are typically chosen based on the results of antimicrobial susceptibility testing performed on bacteria traditionally grown in a planktonic mode (grown in a liquid). |
| PubMedID- 23382856 | Background: the genus burkholderia includes pathogenic gram-negative bacteria that cause melioidosis, glanders, and pulmonary infections of patients with cancer and cystic fibrosis. |
| PubMedID- 22150831 | Burkholderia cepacia complex (bcc) bacteria are opportunistic pathogens that cause multiresistant pulmonary infections in patients with cystic fibrosis (cf). |
| PubMedID- 21747788 | A number of aminoglycosides are commonly used in the treatment of p. aeruginosa infections (e.g., tobramycin, gentamicin, amikacin; gilbert et al., 2003; bartlett, 2004), particularly pulmonary infections in patients with cystic fibrosis (cf) where amikacin and, in particular, tobramycin are routinely employed (canton et al., 2005; taccetti et al., 2008). |
| PubMedID- 21428129 | Health care utilization & costs for cystic fibrosis patients with pulmonary infections. |
| PubMedID- 20093293 | Pseudomonas aeruginosa is the major aetiological agent of chronic pulmonary infections in patients with cystic fibrosis (cf). |
| PubMedID- 22558432 | Background: given the polymicrobial nature of pulmonary infections in patients with cystic fibrosis (cf), it is essential to enhance our knowledge on the composition of the microbial community to improve patient management. |
Page: 1